Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
NSR｜HuidaGene's Yang Hui team pioneers disruptive guanine (G) base editor
2023.05.19 13:38
Views:2517
Follow Us on Social Media
Related
recommendations
recommendations
-
Dec 12,2024
HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed
-
Nov 04,2024
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
-
Apr 11,2025
HuidaGene at CRISPR MEDiCiNE 2025: A Celebration of Progress, Promise, and Patients
-
Sep 06,2023
HuidaGene Therapeutics Announces First Patient Dosed Of The World's First Novel CRISPR/Cas13 RNA-Editing Therapy HG202 For Neovascular Age-related Macular Degeneration